Fig. 1 · Structure

Documents & Downloads

Azithromycin

Cat. No. A11803 CAS 83905-01-5
Azithromycin is an azalide antibiotic, which inhibits the growth of gram negative bacteria, such as Haemophilus influenza.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Azithromycin binds in the ribosomal exit tunnel near the peptidyl-transferase center. In a Thermus thermophilus 70S crystal complex, one bound azithromycin molecule was observed. Its orientation agreed with the compared Haloarcula marismortui model but differed from an earlier Deinococcus radiodurans model. This structural experiment does not establish a functional IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
protein synthesis

Cellular Effect

Cell Line Activity Value Description Reference
A549 CC50 > 600 μM Cytotoxicity against human A549 cells by MTT assay [PMID: 32871342]
HeLa IC50 160 μg/mL Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs [PMID: 17088489]
HeLa IC50 240 μg/mL Antiproliferative effect against HeLa cells after 48 hrs [PMID: 17088489]
HepG2 IC50 > 50 μM Cytotoxicity against human HepG2 cells after 1 to 4 hrs by MTS assay [PMID: 21476508]
HepG2 IC50 > 50 μM Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay [PMID: 22148880]
HepG2 IC50 203 μM Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay [PMID: 22380766]
HepG2 IC50 203 μM Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay [PMID: 22321992]
HFF CC50 174 μM Cytotoxicity against HFF after 48 hrs by MTS assay [PMID: 21428405]
MG-63 IC50 180 μg/mL Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs [PMID: 17088489]
MG-63 IC50 190 μg/mL Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs [PMID: 17088489]
Osteoblast IC50 160 μg/mL Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs [PMID: 17088489]
Osteoblast IC50 25 μg/mL Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs [PMID: 17088489]
THP-1 IC50 > 50 μM Cytotoxicity against human THP1 cells after 1 to 4 hrs by MTS assay [PMID: 21476508]
THP-1 EC50 0.024 mg/L Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs [PMID: 19564365]
THP-1 EC50 2.86 mg/L Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs [PMID: 19564365]
Vero CC50 > 130 μM Cytotoxicity against African green monkey Vero cells by MTT assay [PMID: 32871342]
Vero CC50 > 40 μM Cytotoxicity against African green monkey Vero cells by Celltiter blue assay [PMID: 32871342]
Vero CC50 810 μM Antiproliferative against African green monkey Vero cells incubated for 40 hrs by Celltiter assay [PMID: 32871342]
Vero C1008 CC50 > 40 μM Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) 10.1101/2020.04.03.023846
Vero C1008 EC50 2.12 μM Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days 10.1101/2020.04.03.023846

20 records · Scroll to view more

In Vitro Studies

In U2OS cells, azithromycin increased eIF2α Ser51 phosphorylation after 16 hours at 10–40 μM. This cellular stress-response endpoint does not establish therapeutic efficacy. [2]

In U2OS tandem RFP-GFP-LC3 reporter cells, azithromycin increased the autophagic-flux inhibition score after 6 hours at 10–40 μM. Increased LC3 puncta should therefore not be interpreted as increased completion of autophagy. [2]

Azithromycin binding in a 70S ribosomal crystal complex

Biochemical assay · Thermus thermophilus HB8 70S ribosome crystals [1]

A single azithromycin binding site was modeled in the exit tunnel. The observed orientation resembles the compared archaeal complex and disagrees with an earlier bacterial structural model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bound azithromycin in the 70S ribosomal complexStructural occupancy One azithromycin molecule observed; Fig. 2D difference map at 3.2 Å, contoured at +3σ[1]

Literature-Reported Treatment Conditions

Treatment concentration
500 μM crystal-soaking concentration
Exposure duration
Overnight
Method
Soaking into cryostabilized ribosome crystals
Reported limits
Azithromycin supplier, lot and hydrate/salt form are not specified in the read main methods; soaking concentration is not an IC50.
Methods and source locations

Compound reported in the paper: Azithromycin; Compound label in the paper: Azithromycin

Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.

Fig. 2D–F; Results: Azithromycin; Materials and Methods

Bound azithromycin in the 70S ribosomal complex: X-ray crystallography with unbiased Fo−Fc difference electron density and structural overlays — Fig. 2D–F and caption; Azithromycin subsection

Azithromycin-induced eIF2α phosphorylation

Cell-based study · Human U2OS osteosarcoma cells [2]

Azithromycin increased the cytoplasmic phospho-eIF2α signal relative to vehicle. Tunicamycin and thapsigargin served as positive controls. Other ER-stress reporters in Fig. 2 showed smaller responses than positive controls; the selected endpoint is phosphorylation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cytoplasmic eIF2α Ser51 phosphorylationNormalized immunofluorescence intensity Increased with azithromycin at 10, 20 and 40 μM; means ± SD of four replicates; significance compared with vehicle control[2]

Literature-Reported Treatment Conditions

Treatment concentration
10, 20, 40 μM
Exposure duration
16 h
Method
Azithromycin alone; comparator positive controls: tunicamycin or thapsigargin, each 3 μM
Co-treatment
No azithromycin combination in the adopted experiment
Reported limits
Caption identifies vehicle control but solvent identity is not specified in the read methods; no exact numerical intensity inferred from bars.
Methods and source locations

Compound reported in the paper: Azithromycin; Compound label in the paper: AZT

Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.

Fig. 2A,B; Results first subsection; Cell culture and chemicals; Immunofluorescence

Cytoplasmic eIF2α Ser51 phosphorylation: Phosphoepitope-specific immunofluorescence; automated microscopy — Fig. 2A,B and caption; Immunofluorescence; Statistical analysis

Azithromycin inhibition of autophagic flux

Cell-based study · Human U2OS cells expressing tandem RFP-GFP-LC3 [2]

Azithromycin increased the autophagic-flux inhibition score relative to vehicle. Torin 1 and bafilomycin A1 supplied induction and flux-inhibition comparator controls. The reporter readout distinguishes punctum accumulation from productive degradation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RFP+GFP+ and RFP+GFP− LC3 puncta used to calculate flux inhibitionAutophagic-flux inhibition score Increased at 10, 20 and 40 μM; means ± SD of 4 replicates; compared with vehicle control[2]

Literature-Reported Treatment Conditions

Treatment concentration
10, 20, 40 μM
Exposure duration
6 h
Method
Azithromycin alone; controls include torin 1 (300 nM) and bafilomycin A1 (100 nM)
Co-treatment
No azithromycin combination in the adopted experiment
Reported limits
Vehicle solvent not specified in the read methods; exact score values not tabulated in the inspected evidence and not estimated from bars.
Methods and source locations

Compound reported in the paper: Azithromycin; Compound label in the paper: AZT

Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.

Supplemental Fig. S2A,B and S2 legend; Results first subsection; Cell culture and chemicals; High-content microscopy

RFP+GFP+ and RFP+GFP− LC3 puncta used to calculate flux inhibition: Tandem fluorescent LC3 reporter microscopy after fixation — Supplemental Fig. S2A,B and S2 legend; High-content microscopy

In Vivo Studies

In female SWISS mice, azithromycin pretreatment reduced bronchoalveolar leukocyte, lymphocyte and neutrophil counts, IL-1β, and 8-isoprostane after lung ischaemia and 4 hours of reperfusion. Macrophage counts were unchanged, and MCP-1, KC and IL-6 did not differ significantly between reperfusion groups. These findings concern a short-term sterile injury model with pretreatment. [3]

Azithromycin pretreatment in sterile lung ischaemia/reperfusion

Animal study · Female SWISS outbred mice (20–25 g); six randomized groups, n = 6 per group [3]

Pretreatment attenuated selected inflammatory and oxidative-stress endpoints after reperfusion. Macrophage counts were not significantly altered; MCP-1, KC and IL-6 did not significantly differ between treated and water reperfusion groups. Thoracotomy-only controls showed no treatment impact on measured parameters.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BAL leukocyte differential, IL-1β and 8-isoprostane after reperfusionBetween-group endpoint comparison Lower leukocytes, lymphocytes, neutrophils, IL-1β and 8-isoprostane with azithromycin; no significant macrophage-count difference; n = 6/group; results reported as mean ± SD[3]
MCP-1, KC and IL-6 in BAL after reperfusionP values for azithromycin versus water MCP-1: P = 0.63; KC: P = 0.25; IL-6: P = 0.37; no significant between-reperfusion-group differences[3]

Conditions shared by the study groups

Route
Gavage
Frequency
Every other day
Treatment course
2 weeks before endpoint; injury on day 14
Vehicle
Water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Azithromycin pretreatment + ischaemia/reperfusion
3.8 mg/kg in 125 μL water
Water-treated reperfusion group; additional water/azithromycin thoracotomy-only and ischaemia-only groups in the six-group designLower BAL leukocytes, lymphocytes, neutrophils, IL-1β and 8-isoprostane; macrophages unchanged. MCP-1, KC and IL-6 differences not significant.[3]
Water + ischaemia/reperfusion
125 μL water
Water-treated reperfusion group; additional water/azithromycin thoracotomy-only and ischaemia-only groups in the six-group designMatched reperfusion control for azithromycin pretreatment.[3]
Azithromycin pretreatment + ischaemia/reperfusion
Model: Female SWISS outbred mice, 20–25 g; 90 min left lung ischaemia followed by 4 h reperfusion; n = 6/group
Reported limits: Azithromycin supplier, lot and salt/hydrate are not specified in the read methods.
Water + ischaemia/reperfusion
Model: Female SWISS outbred mice, 20–25 g; 90 min left lung ischaemia followed by 4 h reperfusion; n = 6/group
Reported limits: Azithromycin supplier, lot and salt/hydrate are not specified in the read methods.
Methods and source locations

Compound reported in the paper: Azithromycin; Compound label in the paper: AZI

Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.

Experimental groups, p. 689; Results, pp. 690–691; Figs. 1–3; Statistical analysis, p. 690

BAL leukocyte differential, IL-1β and 8-isoprostane after reperfusion: Total/differential BAL cell counts; IL-1β ELISA; 8-isoprostane EIA — Results, pp. 690–691; Figs. 1–3; shared assay methods and statistics

MCP-1, KC and IL-6 in BAL after reperfusion: Multiplex cytometric bead array; reported group comparisons — Results, p. 691; Fig. 2b,e,h

Azithromycin pretreatment + ischaemia/reperfusion · Experimental groups, p. 689; Results, pp. 690–691; Figs. 1–3; Statistical analysis, p. 690

Water + ischaemia/reperfusion · Experimental groups, p. 689; Results, pp. 690–691; Figs. 1–3; Statistical analysis, p. 690

Specifications

Manufacturer Adooq Bioscience
CAS Number 83905-01-5
Formula C38H72N2O12
Molecular Weight 748.99
Synonyms Zithromax
SMILES
CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (113.48 mM)
Water Insoluble
Ethanol 85 mg/mL (113.48 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] David Bulkley, C. Axel Innis, Gregor Blaha, et al. Revisiting the structures of several antibiotics bound to the bacterial ribosome Proceedings of the National Academy of Sciences of the United States of America (2010). PMID: 20876130 DOI: 10.1073/pnas.1008685107 Source material
  2. [2] Ai-Ling Tian, Qi Wu, Peng Liu, et al. Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response Cell Death & Disease (2021). PMID: 33414432 DOI: 10.1038/s41419-020-03324-w Source material
  3. [3] Nele Geudens, Lien Timmermans, Hadewijch Vanhooren, et al. Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury Transplant International (2008). PMID: 18435685 DOI: 10.1111/j.1432-2277.2008.00670.x Source material

Publications

1 publication citing this product

Added to your cart

View Cart Checkout
Loading...